2994836
Last Update Posted: 2023-03-01
Recruiting has ended
All Genders accepted | 18 Years + |
139 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )
This study will be a multicentre prospective randomized trial to assess the percentage of patients with IBD who, after stopping anti-TNF treatment, have sustained clinical remission at one year compared to those in which the treatment is continued at stable doses
A multicentre prospective randomized trial.
Hypothesis:
The discontinuation of anti-TNF treatment in inflammatory bowel disease (IBD) patients in clinical remission is associated with an increased risk of recurrence compared with maintaining such treatment.
Main objective:
To assess the percentage of patients with IBD who, after stopping anti-TNF treatment, have sustained clinical remission at one year compared to those in which the treatment is continued at stable doses
Secondary objectives:
To compare treatment discontinuation vs. treatment continuation of anti-TNF agents in patients with Crohn´s disease or ulcerative colitis in terms of:
- remission (relapse-free) time,
- phenotype changes with both strategies
- mucosal healing,
- radiologic healing
- impact on quality of life and productivity
- safety
- to identify relapse predictive factors.
- To identify relapse predictive factors after anti-TNF drug discontinuation
- Determining the profile of serum cytokines in patients with both strategies, depending on drug exposure and if maintained clinical remission or relapse.
Planned number of subject to be included: 194
The participation of at 50 hospitals in Spain with an inclusion of about 5 patients per hospital is required..
Case report Form was designed on REDCap (a free, secure, web-based application designed to support data capture for research studies).
Eligibility
Relevant conditions:
Crohn's Disease
Inflammatory Bowel Disease
Ulcerative Colitis
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
Inclusion criteria
Exclusion criteria
locations
Contact Information
Overall Contact
No valid contacts available
Data sourced from ClinicalTrials.gov